Completed PHASE2 INTERVENTIONAL 1-arm NCT02101606

Penumbral Based Novel Thrombolytic Therapy in Acute Ischemic Stroke (TIAS)

Sponsor: University of Alberta

Conditions Brain Ischemia Cerebral Infarction Stroke

Interventions Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg)

Updated 6 times since 2017 Last updated: Apr 4, 2018 Started: Oct 31, 2009 Primary completion: Nov 30, 2017 Completion: Nov 30, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Brain Ischemia and Cerebral Infarction, this trial is completed. The trial is conducted by University of Alberta and has accumulated 6 data snapshots since 2009. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
May 2018 — Jun 2018 [monthly]

Completed PHASE2

Status: Recruiting → Completed

▶ Show 1 earlier version

Jan 2017 — May 2018 [monthly]

Recruiting PHASE2

First recorded

Oct 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Alberta

Data source: University of Alberta

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Edmonton, Canada